ASLAN Pharmaceuticals Limited (ASLN)
Fuera de horario:
ASLAN Pharmaceuticals Limited
3 Temasek Avenue
Level 18 Centennial Tower
Singapore 039190
Singapore
65 6817 9598
https://aslanpharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 35
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Carl Alan Jason Morton Firth EMBA, Ph.D. | Founder, CEO & Executive Director | N/D | N/D | 1973 |
| Mr. Kiran Kumar Asarpota | COO & Head of Finance | N/D | N/D | 1979 |
| Mr. Ben Goodger | General Counsel | N/D | N/D | 1963 |
| Mr. Stephen Doyle | Chief Business Officer | N/D | N/D | 1973 |
| Dr. Alexandre Kaoukhov M.D. | Chief Medical Officer | N/D | N/D | 1974 |
| Charlie Hsu | Investor Relations Director | N/D | N/D | N/D |
| Chi-Chin Wang | IR & Corporate Development Director | N/D | N/D | N/D |
Descripción
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.
Gestión corporativa
La calificación ISS Governance QuickScore de ASLAN Pharmaceuticals Limited a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
